NET ASSET VALUE – 31 January 2026
NET ASSET VALUE – 31 January 2026
2026-02-03 08:00:00
On the 31 January 2026 Flerie AB's Net Asset Value (NAV) was SEK 3,285 million and NAV per share was SEK 42.41. Return on NAV per share in the month was -2.73%.
| Allocation of NAV | Share of portfolio company | Fair value (MSEK) | Part of NAV per share (SEK) | Share of NAV |
| Product Development | ||||
| Prokarium | 50% | 271 | 3.50 | 8.3% |
| Empros Pharma | 79% | 204 | 2.64 | 6.2% |
| Atrogi | 44% | 197 | 2.54 | 6.0% |
| KAHR Medical | 34% | 190 | 2.45 | 5.8% |
| Xspray Pharma | 18% | 180 | 2.33 | 5.5% |
| Bonsai Biotherapeutics | 100% | 153 | 1.97 | 4.6% |
| Xintela | 60% | 151 | 1.94 | 4.6% |
| Lipum | 42% | 143 | 1.85 | 4.4% |
| Microbiotica | 10% | 121 | 1.57 | 3.7% |
| AnaCardio | 13% | 79 | 1.02 | 2.4% |
| Mendus | 23% | 74 | 0.95 | 2.2% |
| Geneos Therapeutics | 15% | 63 | 0.81 | 1.9% |
| EpiEndo Pharmaceuticals | 9% | 52 | 0.67 | 1.6% |
| Vitara Biomedical | 11% | 50 | 0.64 | 1.5% |
| Buzzard Pharmaceuticals | 14% | 32 | 0.41 | 1.0% |
| Egetis Therapeutics | 1% | 25 | 0.33 | 0.8% |
| Amarna Therapeutics | 58% | 11 | 0.14 | 0.3% |
| Strike Pharma | 18% | 11 | 0.14 | 0.3% |
| Alder Therapeutics | 30% | 0 | 0.00 | 0.0% |
| Total | 2,006 | 25.90 | 61.1% | |
| Commercial Growth | ||||
| NorthX Biologics | 61% | 202 | 2.61 | 6.1% |
| Symcel | 30% | 192 | 2.48 | 5.8% |
| Chromafora | 28% | 131 | 1.69 | 4.0% |
| Frontier Biosolutions | 2% | 25 | 0.33 | 0.8% |
| Nanologica | 44% | 15 | 0.20 | 0.5% |
| Bohus Biotech | 45% | 0 | 0.00 | 0.0% |
| Total | 566 | 7.30 | 17.2% | |
| Assets related to Portfolio companies | 225 | 2.91 | 6.9% | |
| Other assets and liabilities | 487 | 6.29 | 14.8% | |
| Net Asset Value | 3,285 | 42.41 | 100.0% | |